NCCN Urothelial Cancer Practice Guidelines

Howard Scher, Robert Bahnson, Samuel Monroe Cohen, Mario Eisenberger, Harry Herr, James Kozlowski, Paul Lange, James Montie, Alan Pollack, Derek Raghaven, Jerome Richie, William Shipley

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Urothelial tumors represent a spectrum of diseases with a range of prognoses. Once a diagnosis is established at any point on the urothelial tract, the patient remains at risk for developing a new lesion at a different or the same location, at a similar or more advanced stage. Continued monitoring for recurrence is an essential part of management, as most recurrences are superficial and can be managed by endoscopic means. Within each category of disease, more refined methods to determine prognosis and guide management, based on molecular staging, are under development. These methods are aimed at optimizing the individual patient's likelihood of cure and chance for organ preservation. For patients with more extensive disease, newer treatments typically involve combined-modality approaches using recently developed surgical procedures, or three-dimensional treatment planning for more precise delivery of radiation therapy. While these are not appropriate in all cases, they do offer the promise of an improved quality of life and prolonged survival. Finally, within the category of metastatic disease, a number of new agents have been identified that appear to be superior to those currently considered to be standard therapies. It is thought, therefore, that the treatment of urothelial tumors will evolve rapidly over the next few years, with improved outcomes for patients with all stages of disease.

Original languageEnglish (US)
Pages (from-to)225-271
Number of pages47
JournalONCOLOGY
Volume12
Issue number7 A
StatePublished - Aug 28 1998

Fingerprint

Practice Guidelines
Neoplasms
Organ Preservation
Recurrence
Therapeutics
Radiotherapy
Quality of Life
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Scher, H., Bahnson, R., Cohen, S. M., Eisenberger, M., Herr, H., Kozlowski, J., ... Shipley, W. (1998). NCCN Urothelial Cancer Practice Guidelines. ONCOLOGY, 12(7 A), 225-271.

NCCN Urothelial Cancer Practice Guidelines. / Scher, Howard; Bahnson, Robert; Cohen, Samuel Monroe; Eisenberger, Mario; Herr, Harry; Kozlowski, James; Lange, Paul; Montie, James; Pollack, Alan; Raghaven, Derek; Richie, Jerome; Shipley, William.

In: ONCOLOGY, Vol. 12, No. 7 A, 28.08.1998, p. 225-271.

Research output: Contribution to journalArticle

Scher, H, Bahnson, R, Cohen, SM, Eisenberger, M, Herr, H, Kozlowski, J, Lange, P, Montie, J, Pollack, A, Raghaven, D, Richie, J & Shipley, W 1998, 'NCCN Urothelial Cancer Practice Guidelines', ONCOLOGY, vol. 12, no. 7 A, pp. 225-271.
Scher H, Bahnson R, Cohen SM, Eisenberger M, Herr H, Kozlowski J et al. NCCN Urothelial Cancer Practice Guidelines. ONCOLOGY. 1998 Aug 28;12(7 A):225-271.
Scher, Howard ; Bahnson, Robert ; Cohen, Samuel Monroe ; Eisenberger, Mario ; Herr, Harry ; Kozlowski, James ; Lange, Paul ; Montie, James ; Pollack, Alan ; Raghaven, Derek ; Richie, Jerome ; Shipley, William. / NCCN Urothelial Cancer Practice Guidelines. In: ONCOLOGY. 1998 ; Vol. 12, No. 7 A. pp. 225-271.
@article{1f5f46d510fc4199ae6661b4542686f2,
title = "NCCN Urothelial Cancer Practice Guidelines",
abstract = "Urothelial tumors represent a spectrum of diseases with a range of prognoses. Once a diagnosis is established at any point on the urothelial tract, the patient remains at risk for developing a new lesion at a different or the same location, at a similar or more advanced stage. Continued monitoring for recurrence is an essential part of management, as most recurrences are superficial and can be managed by endoscopic means. Within each category of disease, more refined methods to determine prognosis and guide management, based on molecular staging, are under development. These methods are aimed at optimizing the individual patient's likelihood of cure and chance for organ preservation. For patients with more extensive disease, newer treatments typically involve combined-modality approaches using recently developed surgical procedures, or three-dimensional treatment planning for more precise delivery of radiation therapy. While these are not appropriate in all cases, they do offer the promise of an improved quality of life and prolonged survival. Finally, within the category of metastatic disease, a number of new agents have been identified that appear to be superior to those currently considered to be standard therapies. It is thought, therefore, that the treatment of urothelial tumors will evolve rapidly over the next few years, with improved outcomes for patients with all stages of disease.",
author = "Howard Scher and Robert Bahnson and Cohen, {Samuel Monroe} and Mario Eisenberger and Harry Herr and James Kozlowski and Paul Lange and James Montie and Alan Pollack and Derek Raghaven and Jerome Richie and William Shipley",
year = "1998",
month = "8",
day = "28",
language = "English (US)",
volume = "12",
pages = "225--271",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "7 A",

}

TY - JOUR

T1 - NCCN Urothelial Cancer Practice Guidelines

AU - Scher, Howard

AU - Bahnson, Robert

AU - Cohen, Samuel Monroe

AU - Eisenberger, Mario

AU - Herr, Harry

AU - Kozlowski, James

AU - Lange, Paul

AU - Montie, James

AU - Pollack, Alan

AU - Raghaven, Derek

AU - Richie, Jerome

AU - Shipley, William

PY - 1998/8/28

Y1 - 1998/8/28

N2 - Urothelial tumors represent a spectrum of diseases with a range of prognoses. Once a diagnosis is established at any point on the urothelial tract, the patient remains at risk for developing a new lesion at a different or the same location, at a similar or more advanced stage. Continued monitoring for recurrence is an essential part of management, as most recurrences are superficial and can be managed by endoscopic means. Within each category of disease, more refined methods to determine prognosis and guide management, based on molecular staging, are under development. These methods are aimed at optimizing the individual patient's likelihood of cure and chance for organ preservation. For patients with more extensive disease, newer treatments typically involve combined-modality approaches using recently developed surgical procedures, or three-dimensional treatment planning for more precise delivery of radiation therapy. While these are not appropriate in all cases, they do offer the promise of an improved quality of life and prolonged survival. Finally, within the category of metastatic disease, a number of new agents have been identified that appear to be superior to those currently considered to be standard therapies. It is thought, therefore, that the treatment of urothelial tumors will evolve rapidly over the next few years, with improved outcomes for patients with all stages of disease.

AB - Urothelial tumors represent a spectrum of diseases with a range of prognoses. Once a diagnosis is established at any point on the urothelial tract, the patient remains at risk for developing a new lesion at a different or the same location, at a similar or more advanced stage. Continued monitoring for recurrence is an essential part of management, as most recurrences are superficial and can be managed by endoscopic means. Within each category of disease, more refined methods to determine prognosis and guide management, based on molecular staging, are under development. These methods are aimed at optimizing the individual patient's likelihood of cure and chance for organ preservation. For patients with more extensive disease, newer treatments typically involve combined-modality approaches using recently developed surgical procedures, or three-dimensional treatment planning for more precise delivery of radiation therapy. While these are not appropriate in all cases, they do offer the promise of an improved quality of life and prolonged survival. Finally, within the category of metastatic disease, a number of new agents have been identified that appear to be superior to those currently considered to be standard therapies. It is thought, therefore, that the treatment of urothelial tumors will evolve rapidly over the next few years, with improved outcomes for patients with all stages of disease.

UR - http://www.scopus.com/inward/record.url?scp=0344843277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344843277&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 225

EP - 271

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 7 A

ER -